Serum miR-29a as a Marker of Multiple Myeloma

Investor logo

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

ŠEVČÍKOVÁ Sabina KUBICZKOVÁ Lenka SEDLAŘÍKOVÁ Lenka SLABÝ Ondřej HÁJEK Roman

Year of publication 2013
Type Article in Periodical
Magazine / Source Leukemia & Lymphoma
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.3109/10428194.2012.704030
Field Oncology and hematology
Keywords miR-29a; serum; microRNA; multiple myeloma
Attached files
Description MicroRNA (miRNA) are short non-coding RNA about 21-25 nucleotides long; they were reported to be involved in initiation and progression of solid tumors as well as hematological malignancies.Moreover, circulating miRNA were observed in serum. These circulating serum miRNA are very stable, resistant to RNAse treatment and differ between healthy subjects and patients with colorectal and lung cancer as well as diabetes. Nowadays, there are no specific markers for MM prediction. With the introduction of novel drugs and a very real possibility of targeted therapy in the near future, these markers are becoming increasingly important. If a specific marker was found in peripheral blood, it would be easily accessible and could be obtained at various time points of treatment and even in the time of remission for frequent monitoring.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.